Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | KDM6B | O15054 | 1/20 | 0.53 |
| ▸ | TET3 | O43151 | 1/20 | 0.53 |
| ▸ | KDM4A | O75164 | 1/20 | 0.53 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.53 |
| ▸ | KDM5A | P29375 | 1/20 | 0.53 |
| ▸ | KDM5C | P41229 | 1/20 | 0.53 |
| ▸ | ASPH | Q12797 | 1/20 | 0.53 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.53 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.53 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.53 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.53 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.53 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.53 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.53 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.53 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9440315 | 0.98 | ALDH1A1 (0.52) | ALDH1A1KDM4EMAPTKDM6BTET3 | |
| SCHEMBL9440318 | 0.98 | ALDH1A1 (0.52) | ALDH1A1KDM4EMAPTKDM6BTET3 | |
| SCHEMBL3092547 | 0.84 | TSHR (0.50) | ALDH1A1KDM4EMAPTSMN1; SMN2CYP3A4 | |
| Zinc Ion SCHEMBL9440309 | 0.84 | CA1 (0.44) | ALDH1A1KDM4EMAPTSMN1; SMN2TP53 | |
| SCHEMBL1850044 | 0.80 | GSK3B (0.51) | ALDH1A1KDM4EMAPTSMN1; SMN2PYGL | |
| SCHEMBL4037805 | 0.80 | ALDH1A1 (0.49) | ALDH1A1KDM4EMAPTPYGLPYGM | |
| SCHEMBL3639473 | 0.79 | KDM4E (0.52) | ALDH1A1KDM4EMAPTTP53PYGL | |
| SCHEMBL29851386 | 0.79 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTSMN1; SMN2PYGL | |
| SCHEMBL18957459 | 0.79 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTSMN1; SMN2PYGL | |
| SCHEMBL31009101 | 0.78 | NPC1 (0.41) | ALDH1A1KDM4EMAPTSMN1; SMN2PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1631560-A2 | C-FMS KINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-03-08 | — | — | EP | claimed |
| US-20050004112-A1 | C-fms kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | claimed |
| WO-2004096795-A2 | C-FMS KINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-11-11 | — | — | WO | claimed |
| US-20260144743-A1 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-05-28 | — | — | US | disclosed |
| EP-4699655-A2 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-02-25 | — | — | EP | disclosed |
| US-12377105-B2 | Compounds | TMEM16A LIMITED (GB) | 2025-08-05 | — | — | US | disclosed |
| CN-119751456-A | Spiro compounds | C4医药公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119490451-A | Compounds as positive modulators of calcium activated chloride channels | TMEM16A有限公司 | 2025-02-21 | — | — | CN | disclosed |
| CN-112312904-B | Spiro compounds | C4医药公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-111683926-B | Compounds of formula (I) | 企业治疗学有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-20230416251-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | US | disclosed |
| EP-0583479-A1 | REMEDY FOR DERMATOPATHY AND METALLOTHIONEIN INDUCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-02-23 | — | — | EP | disclosed |
| CN-1023479-C | Process for preparing monoamide derivatives of ethylenediamine | HOFFMANN LA ROCHE (CH) | 1994-01-12 | — | — | CN | disclosed |
| US-5219847-A | Antipruritic composition | SHISEIDO COMPANY, LTD. (JP) | 1993-06-15 | — | — | US | disclosed |
| EP-0433457-A1 | ANTIPRURITIC COMPOSITION | SHISEIDO COMPANY LIMITED (JP) | 1991-06-26 | — | — | EP | disclosed |
| US-4764522-A | ANTIDEPRESSANT, ANTIPARKINSON DISEASE | HOFFMANN-LA ROCHE INC. (US) | 1988-08-16 | — | — | US | disclosed |
| CN-85107182-A | Process for preparing monoamide derivatives of ethylenediamine | — | 1987-04-08 | — | — | CN | disclosed |
| EP-0053789-B1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITION, USEFUL AS AN ANTI-ALLERGIC AGENT | Tanabe Seiyaku Co., Ltd. (JP) | 1985-03-27 | — | — | EP | disclosed |
| US-4404214-A | 2-Pyridinecarboxamide derivatives compositions containing same and method of using same | TANABE SEIYAKU CO., LTD. (JP) | 1983-09-13 | — | — | US | disclosed |
| EP-0053789-A1 | 2-Pyridinecarboxamide derivative, process for preparing same and pharmaceutical composition, useful as an anti-allergic agent | Tanabe Seiyaku Co., Ltd. (JP) | 1982-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144743-A1 | COMPOUNDS | CACNA1E, TMEM109, CACNA1C | ALDH1A1 1592/4885KDM4E 3794/4885MAPT 2049/4885 |
| US-20230416251-A1 | SPIROCYCLIC COMPOUNDS | CRBN, RBX1, XIAP | ALDH1A1 2000/4885KDM4E 1861/4885MAPT 3398/4885 |
| US-20050004112-A1 | C-fms kinase inhibitors | FLT3, FGR, FER | ALDH1A1 4574/4885KDM4E 1258/4885MAPT 429/4885 |
| US-12377105-B2 | Compounds | CACNA1E, TMEM109, CACNA1A | ALDH1A1 2218/4885KDM4E 3113/4885MAPT 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.